论文部分内容阅读
比索洛尔(Bisoprolol.康可,Concor)是1985年德国MERCK公司投入市场的高度选择性β_1受体阻滞剂,口服后几乎全部(>90%)被吸收,空腹或早餐时服用不影响其吸收率,首过效应小、生物利用度达88%,口服后1.5～3小时达最高血浆水平,半衰期10～12小时.每日服用1次即可.我们观察了比索洛尔治疗原发性高血压的疗效和安全性.报道如下.1 资料与方法1.1 病例选择 选择原发性高血压患者为研究对象,入选患者近2周内均未用过可能对血压有影响的药物,并经过连续3日每日1次测量血压,对平均收缩压>21.3kPa或(和)平均舒张压>12.6kPa者方可进入治疗期.对有β受体阻滞剂禁忌症者不列入本研究.人选共64例,男38例.女26例;年龄33～68
Bisoprolol (Concor), a highly selective beta-1 blocker marketed by the German company MERCK in 1985, almost completely (> 90%) is absorbed orally and does not affect its fasting or breakfast intake Absorption rate, the first pass effect is small, the bioavailability of 88%, 1.5 to 3 hours after oral administration of the highest plasma levels, half-life of 10 to 12 hours a day to 1. We observed bisoprolol treatment of primary Efficacy and safety of hypertension.Report as follows.1 Materials and Methods1.1 Case SelectionHypertensive patients were selected as the research object, the selected patients within the past 2 weeks have not used drugs that may have an impact on blood pressure, and after continuous On the 3rd, the blood pressure was measured once a day, and the average systolic blood pressure> 21.3 kPa or (mean) diastolic blood pressure> 12.6 kPa was entered into the treatment period, and those with contraindications to β-blockers were not included in this study. A total of 64 candidates, 38 males and 26 females; aged 33 to 68